Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing ...
ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio has filed a WARN ...
As it continues construction, ImmunityBio noted in a quarterly regulatory filing that it believes governmental funding will assist in funding a portion of the further build-out in Dunkirk. As of March ...
Dunkirk's state-of-the-art facility is expected to play a significant role in the production of a new cancer-fighting drug developed by ImmunityBio Inc. On Tuesday, the company announced in a news ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...
ImmunityBio Inc. probably won't ramp up hiring at its Dunkirk plant for a couple years, the city's planning and development director said last week. Vince DeJoy gave a mostly upbeat update about the ...
Hosted on MSN
Why ImmunityBio stock is down more than 20% today
The United States’ Food & Drug Administration is being forced to repeatedly address the same issue with ImmunityBio’s management. Ironically, the biopharma company’s addressable actions don’t offer a ...
DUNKIRK, N.Y. — ImmunityBio has filed a WARN notice with the New York state Department of Labor for two layoffs at its plant in Dunkirk. According to the notice, the California-based biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results